The overall goal of this program project is to improve allogeneic hematopoietic cell transplantation (HCT) as treatment for hematological malignancies. Specifically we proposed laboratory and clinical studies to broaden the availability of transplantation, to decrease the incidence and severity of graft-versus-host disease, and to reduce the incidence of malignant disease recurrence post transplant. Four individual projects are proposed: 1. Immunogenetics of Graft-versus-host Disease. 2. Nonmyeloablative Hematopoietic Cell Allotransplants. 3. Specific Adoptive Immunotherapy of Myeloid Malignancy. 4. Targeting T Cell Reactivity for Leukemia Eradication. In addition, core support is requested in biostatistics, molecular diagnostics, cell processing, long-term follow-up, and administration. Our ability to successfully carry out the proposed work is greatly benefited by: (1) the existence of a large group of investigators all focused on the general topic of HCT;(2) strong preclinical research programs at our Center in support of this topic;and, (3) treatment of >500 transplant patients at our Center each year

Public Health Relevance

The Program Project has direct relevance to the >27,000 patients who undergo allogeneic HCT for treatment of hematopoietic malignancies each year. The work proposed promises to increase the availability of transplantation and to make it safer and more effective. Lessons learned from our planned studies will apply to issues of transplant tolerance, the molecular basis of malignant disease progression, and especially the immunotherapy of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-T (M1))
Program Officer
Merritt, William D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Oda, Shannon K; Daman, Andrew W; Garcia, Nicolas M et al. (2017) A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood 130:2410-2419
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2017) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant :
Schmitt, Thomas M; Aggen, David H; Ishida-Tsubota, Kumiko et al. (2017) Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro. Nat Biotechnol 35:1188-1195
Chapuis, Aude G; Desmarais, Cindy; Emerson, Ryan et al. (2017) Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo. Sci Immunol 2:
Hill, Joshua A; Mayer, Bryan T; Xie, Hu et al. (2017) The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood 129:2316-2325
Inamoto, Yoshihiro; Lee, Stephanie J (2017) Late effects of blood and marrow transplantation. Haematologica 102:614-625
Stromnes, Ingunn M; Hulbert, Ayaka; Pierce, Robert H et al. (2017) T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res 5:978-991
Shadman, Mazyar; Hingorani, Sangeeta; Lanum, Scott A et al. (2017) Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis - a single institution experience. Leuk Lymphoma 58:740-742
Sala Torra, Olga; Othus, Megan; Williamson, David W et al. (2017) Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biol Blood Marrow Transplant 23:691-696
Fisher, Cynthia E; Hohl, Tobias M; Fan, Wenhong et al. (2017) Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. Blood 129:2693-2701

Showing the most recent 10 out of 1832 publications